Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€72.69

€72.69

-0.290%
-0.21
-0.290%
-

-

 
15:37 / Tradegate WKN: A3D3G6 / Name: Ge Healthcare Technologies Inc / Stock / ? /

Ge Healthcare Technologies Inc Stock

The price for the Ge Healthcare Technologies Inc stock decreased slightly today. Compared to yesterday there is a change of -€0.210 (-0.290%).

Pros and Cons of Ge Healthcare Technologies Inc in the next few years

Pros
?
B****
?
M***** P*******
?
S********** s********
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

GE HealthCare Announces Changes in Strategic Leadership and Key Segments to Better Serve Patients and Customers: https://mms.businesswire.com/media/20230105005172/en/1673594/5/GE_HealthCare_Logo_%28Jan_2023%29.jpg
GE HealthCare Announces Changes in Strategic Leadership and Key Segments to Better Serve Patients and Customers


GE HealthCare (Nasdaq: GEHC) announced today that it has named Roland Rott president and CEO of Imaging and Phil Rackliffe president and CEO of Ultrasound and IGT. Both leaders bring to their roles

GE HealthCare Increases Access to Precision Care Tools, Encouraging the Continued Adoption and Practice of More Personalized Medicine Around the World: https://mms.businesswire.com/media/20230105005172/en/1673594/5/GE_HealthCare_Logo_%28Jan_2023%29.jpg
GE HealthCare Increases Access to Precision Care Tools, Encouraging the Continued Adoption and Practice of More Personalized Medicine Around the World


GE HealthCare once again joins the world’s top medical and academic institutions at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting to discuss today’s healthcare

GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients with Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and Economic Outcomes, Potentially Saving $142M Over Five...: https://mms.businesswire.com/media/20230105005172/en/1673594/5/GE_HealthCare_Logo_%28Jan_2023%29.jpg
GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients with Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and Economic Outcomes, Potentially Saving $142M Over Five...


 



GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients with Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and